Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Period C Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

NCT03649165
View directory record Official record
Conditions
Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 3, 2026, 10:48 PM EDT
Not listed Phase 1 Interventional

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

NCT03129139
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions
Minnelide™Capsules
Drug
Lead sponsor
Minneamrita Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, & Pharmacokinetics of K-285 Compared With Indomethacin Capsule in Healthy Adults

NCT03712241
View directory record Official record
Conditions
Healthy
Interventions
K-285, Indomethacin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

NCT06154447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
12
States / cities
Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

NCT03686033
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Placebo, E2082
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Boise, Idaho • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

NCT05061693
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Phoenix, Arizona • Fountain Valley, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 3, 2026, 10:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3154885 in Healthy Participants

NCT04014361
View directory record Official record
Conditions
Healthy
Interventions
LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skin Surface and Intradermal Temperature Responses to Heat Stress

NCT06593067
View directory record Official record
Conditions
Hyperthermia
Interventions
Control, Fan, Fan and Water Spray, Water Spray
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers

NCT00175084
View directory record Official record
Conditions
Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases
Interventions
Comparison of dietary protein amino acid profile
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

NCT00509093
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Buffalo, New York • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Seltorexant in Healthy Participants

NCT04553042
View directory record Official record
Conditions
Healthy
Interventions
Seltorexant
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00078403
View directory record Official record
Conditions
HIV Infections, Hepatitis C, Liver Disease
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

Pharmacokinetic and Subjective Effects of Heated Tobacco Products

NCT06356610
View directory record Official record
Conditions
Tobacco Use
Interventions
Product A, Product B, Product C, Product D, Product E, Product F
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Lexington, Kentucky • Springfield, Missouri • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

NCT05140096
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Fluconazole, Isavuconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 3, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GHZ339, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

NCT02723630
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenvatinib 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

NCT02164539
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, UMEC, VI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Newport Beach, California • San Diego, California • Upland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

NCT03919409
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-161, TS-161 Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
View directory record Official record
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

NCT02557100
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Adalimumab, Methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 3, 2026, 10:48 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

NCT07622433
View directory record Official record
Conditions
Healthy Participants
Interventions
Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP, Laroprovstat/ezetimibe FCDP-slow variant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

NCT04757974
View directory record Official record
Conditions
HIV Infections
Interventions
Fostemsavir 600 mg, Fostemsavir 200 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 3, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

NCT02415790
View directory record Official record
Conditions
Healthy Participants
Interventions
E2027, E2027 matching placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 3, 2026, 10:48 PM EDT